Report Detail

Other Global Anti-tumor Drug Market Size, Status and Forecast 2019-2025

  • RnM3124012
  • |
  • 19 March, 2019
  • |
  • Global
  • |
  • 105 Pages
  • |
  • QYResearch
  • |
  • Other

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
In China, antitumor drugs are also the key areas of concern for many enterprises. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other well-known domestic enterprises in the anti-tumor drugs have invested a lot of money, there are many innovative anti-cancer drugs into the clinical research stage. In the meantime, there has been "explosive" growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future.
China's bio-pharmaceutical industry already has a good foundation; from the national level to local governments at all levels continue to step up efforts to support the development of bio-pharmaceutical industry. The output value of the pharmaceutical industry maintained a growth rate of 20% during the 12th Five-Year Plan period. In 2013, the total output value of the pharmaceutical industry reached 2.1 trillion yuan. However, compared with the bio-pharmaceutical industry in the advanced countries in the world, there is still a huge gap between the biomedical industry in our country and the demand for building an overall well-to-do society. Mainly manifested in: small-scale enterprises, more than 10 billion yuan enterprises and more than one billion yuan less; independent innovation ability is weak, many varieties of imitation with independent intellectual property rights of the few species; restrict some of the long-term development of biomedical industry , Deep-seated problems still exist.
In 2018, the global Anti-tumor Drug market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Anti-tumor Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Anti-tumor Drug development in United States, Europe and China.

The key players covered in this study
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka

Market segment by Type, the product can be split into
Cytotoxic Drugs
Non-cytotoxic Drugs

Market segment by Application, split into
Alkylating Agents
Anti-metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline antitumor drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Anti-tumor Drug status, future forecast, growth opportunity, key market and key players.
To present the Anti-tumor Drug development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Anti-tumor Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Anti-tumor Drug Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Cytotoxic Drugs
      • 1.4.3 Non-cytotoxic Drugs
    • 1.5 Market by Application
      • 1.5.1 Global Anti-tumor Drug Market Share by Application (2014-2025)
      • 1.5.2 Alkylating Agents
      • 1.5.3 Anti-metabolism Drugs
      • 1.5.4 Platinum Antineoplastic Agents
      • 1.5.5 Anthracycline antitumor drugs
      • 1.5.6 Microtubule Stabilizer
      • 1.5.7 Endocrine Therapy Drugs
      • 1.5.8 Immunotherapy Drugs
      • 1.5.9 Gene Therapy Drugs
      • 1.5.10 Targeted Antineoplastic Drugs
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Anti-tumor Drug Market Size
    • 2.2 Anti-tumor Drug Growth Trends by Regions
      • 2.2.1 Anti-tumor Drug Market Size by Regions (2014-2025)
      • 2.2.2 Anti-tumor Drug Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Anti-tumor Drug Market Size by Manufacturers
      • 3.1.1 Global Anti-tumor Drug Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Anti-tumor Drug Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Anti-tumor Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Anti-tumor Drug Key Players Head office and Area Served
    • 3.3 Key Players Anti-tumor Drug Product/Solution/Service
    • 3.4 Date of Enter into Anti-tumor Drug Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Anti-tumor Drug Market Size by Type (2014-2019)
    • 4.2 Global Anti-tumor Drug Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Anti-tumor Drug Market Size (2014-2019)
    • 5.2 Anti-tumor Drug Key Players in United States
    • 5.3 United States Anti-tumor Drug Market Size by Type
    • 5.4 United States Anti-tumor Drug Market Size by Application

    6 Europe

    • 6.1 Europe Anti-tumor Drug Market Size (2014-2019)
    • 6.2 Anti-tumor Drug Key Players in Europe
    • 6.3 Europe Anti-tumor Drug Market Size by Type
    • 6.4 Europe Anti-tumor Drug Market Size by Application

    7 China

    • 7.1 China Anti-tumor Drug Market Size (2014-2019)
    • 7.2 Anti-tumor Drug Key Players in China
    • 7.3 China Anti-tumor Drug Market Size by Type
    • 7.4 China Anti-tumor Drug Market Size by Application

    8 Japan

    • 8.1 Japan Anti-tumor Drug Market Size (2014-2019)
    • 8.2 Anti-tumor Drug Key Players in Japan
    • 8.3 Japan Anti-tumor Drug Market Size by Type
    • 8.4 Japan Anti-tumor Drug Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Anti-tumor Drug Market Size (2014-2019)
    • 9.2 Anti-tumor Drug Key Players in Southeast Asia
    • 9.3 Southeast Asia Anti-tumor Drug Market Size by Type
    • 9.4 Southeast Asia Anti-tumor Drug Market Size by Application

    10 India

    • 10.1 India Anti-tumor Drug Market Size (2014-2019)
    • 10.2 Anti-tumor Drug Key Players in India
    • 10.3 India Anti-tumor Drug Market Size by Type
    • 10.4 India Anti-tumor Drug Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Anti-tumor Drug Market Size (2014-2019)
    • 11.2 Anti-tumor Drug Key Players in Central & South America
    • 11.3 Central & South America Anti-tumor Drug Market Size by Type
    • 11.4 Central & South America Anti-tumor Drug Market Size by Application

    12 International Players Profiles

    • 12.1 Roche
      • 12.1.1 Roche Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Anti-tumor Drug Introduction
      • 12.1.4 Roche Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.1.5 Roche Recent Development
    • 12.2 Novartis
      • 12.2.1 Novartis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Anti-tumor Drug Introduction
      • 12.2.4 Novartis Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.2.5 Novartis Recent Development
    • 12.3 Celgene
      • 12.3.1 Celgene Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Anti-tumor Drug Introduction
      • 12.3.4 Celgene Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.3.5 Celgene Recent Development
    • 12.4 Bristol-Myers Squibb
      • 12.4.1 Bristol-Myers Squibb Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Anti-tumor Drug Introduction
      • 12.4.4 Bristol-Myers Squibb Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.4.5 Bristol-Myers Squibb Recent Development
    • 12.5 Amgen
      • 12.5.1 Amgen Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Anti-tumor Drug Introduction
      • 12.5.4 Amgen Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.5.5 Amgen Recent Development
    • 12.6 Johnson & Johnson
      • 12.6.1 Johnson & Johnson Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Anti-tumor Drug Introduction
      • 12.6.4 Johnson & Johnson Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.6.5 Johnson & Johnson Recent Development
    • 12.7 Pfizer
      • 12.7.1 Pfizer Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Anti-tumor Drug Introduction
      • 12.7.4 Pfizer Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.7.5 Pfizer Recent Development
    • 12.8 Takeda
      • 12.8.1 Takeda Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Anti-tumor Drug Introduction
      • 12.8.4 Takeda Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.8.5 Takeda Recent Development
    • 12.9 Eli Lilly
      • 12.9.1 Eli Lilly Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Anti-tumor Drug Introduction
      • 12.9.4 Eli Lilly Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.9.5 Eli Lilly Recent Development
    • 12.10 AstraZeneca
      • 12.10.1 AstraZeneca Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Anti-tumor Drug Introduction
      • 12.10.4 AstraZeneca Revenue in Anti-tumor Drug Business (2014-2019)
      • 12.10.5 AstraZeneca Recent Development
    • 12.11 Astellas
    • 12.12 Merck & Co
    • 12.13 Sanofi
    • 12.14 Bayer
    • 12.15 Biogen Idec
    • 12.16 Eisai
    • 12.17 Teva
    • 12.18 Otsuka

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Summary:
      Get latest Market Research Reports on Anti-tumor Drug . Industry analysis & Market Report on Anti-tumor Drug is a syndicated market report, published as Global Anti-tumor Drug Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Anti-tumor Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,088.80
      4,633.20
      6,177.60
      3,603.60
      5,405.40
      7,207.20
      590,031.00
      885,046.50
      1,180,062.00
      325,143.00
      487,714.50
      650,286.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report